Chinese
English
Home
Gan & Lee Overview
Company Profile
Company Culture
Marketing Network
Member Companies
Strategic Partners
Gan & Lee History
Contact Us
Newsroom
Media Focus
Company News
Industry News
Honors and Awards
International Business
Products
Insulin Analogue
Medical Devices
R&D
Intellectual Property
Social Responsibility
Diabetes and Insulin
Careers
Why choose Gan & Lee
What we are looking for
What we can offer
Join us
Investor Relations
Annual Reports
Newsroom
Media Focus
Company News
Industry News
Honors and Awards
International Business
Fast Track
Company News
Home
Newsroom
Company News
2021-07-19
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes ...
2021-06-03
Insulin Glargine Injection of Gan & Lee Pharmaceuticals Has Made Significant Commercialization Progress in Russia
2021-04-06
Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma.
2021-02-22
Gan & Lee Announces New Partnership with International Diabetes Federation
2021-02-08
Gan & Lee Pharmaceuticals Has Made Significant Commercialization Progress in Brazil
2021-02-01
Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA
<<
1
2
3
4
5
>>
